Heidelberg, Germany
Molecular Health stands at the forefront of biotechnology and health care innovation, leveraging over 15 years of experience to transform complex biomedical data into actionable insights. With their proprietary Dataome technology, the company excels in integrating and contextualizing molecular and drug-related data, offering profound insights into health and disease etiology.
Founded in 2004 and headquartered in Germany, Molecular Health develops cutting-edge software that enables advanced genetic and molecular data analysis, alongside Pharma AI solutions, which significantly enhance early trial designs, target identification, and biomarker discovery.
The company's last investment was a substantial €25.00M Private Equity Round on 16 November 2015, with funding sourced from dievini Hopp Biotech Holding. As a leader in combining information technology with life sciences, Molecular Health appears well-positioned for impactful contributions and growth within the biomedical software sector.
QIAGEN